FDA approved Vivelle-Dot (Estradiol Transdermal) for Menopausal Symptoms and Osteoporosis PreventionFDA approved Estradiol Skin Patch for Menopause Symptoms and Bone Loss

FDA From the archive Source published July 31, 1996 Summary added November 3, 2026 DOI ↗ Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider adding a progestogen for women with a uterus to reduce endometrial cancer risk.

The U.S. Food and Drug Administration has approved Vivelle-Dot (estradiol transdermal system) for four indications: treatment of moderate to severe vasomotor symptoms due to menopause, treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and prevention of postmenopausal osteoporosis. The approval provides clinicians with a transdermal option for estrogen therapy.

The label includes limitations of use: when prescribing solely for moderate to severe vaginal atrophy, topical vaginal products should be considered first; and when prescribing solely for prevention of postmenopausal osteoporosis, non-estrogen medications should be considered first, with estrogen therapy reserved for women at significant risk of osteoporosis. For women with a uterus, the label recommends considering the addition of a progestogen to reduce the risk of endometrial cancer. Therapy should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman, with periodic reevaluation.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Not reported in label.

Indication & Patient Population

Vivelle-Dot is indicated for: - Treatment of moderate to severe vasomotor symptoms due to menopause. - Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Limitation of use: when prescribing solely for this indication, first consider topical vaginal products. - Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. - Prevention of postmenopausal osteoporosis. Limitation of use: when prescribing solely for this indication, first consider non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.

Dosing & Administration

- For vasomotor symptoms and vulvar/vaginal atrophy: start with Vivelle-Dot 0.0375 mg/day applied to the skin twice weekly. Adjust dosage based on clinical response. - For prevention of postmenopausal osteoporosis: start with Vivelle-Dot 0.025 mg/day applied twice weekly. - In women not currently taking oral estrogens or switching from another estradiol transdermal therapy, treatment may be initiated at once. In women currently taking oral estrogens, initiate Vivelle-Dot 1 week after withdrawal of oral hormone therapy, or sooner if menopausal symptoms reappear in less than 1 week. - Attempt to taper or discontinue Vivelle-Dot at 3- to 6-month intervals. - Give continuously in women without an intact uterus. In women with an intact uterus, give on a cyclic schedule (e.g., 3 weeks on, 1 week off). - Application: place adhesive side on a clean, dry area of the trunk (abdomen or buttocks). Do not apply to the breasts. Replace twice weekly. Rotate sites, allowing at least 1 week between applications to a particular site. Avoid oily, damaged, or irritated skin, and the waistline.

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

Not reported in label.

Place in Therapy

Vivelle-Dot is an estrogen transdermal system for menopausal symptom relief and osteoporosis prevention. The label emphasizes using the lowest effective dose for the shortest duration, with periodic reevaluation. For women with a uterus, consider adding a progestogen to reduce endometrial cancer risk. For vaginal atrophy alone, topical vaginal products should be considered first; for osteoporosis prevention alone, non-estrogen medications should be considered first, reserving estrogen for women at significant risk.

Vivelle-Dot is a skin patch that delivers estradiol, a form of estrogen. The FDA approved it for four uses: moderate to severe hot flashes from menopause, moderate to severe vaginal dryness and discomfort from menopause, low estrogen caused by conditions such as hypogonadism or ovary failure, and prevention of osteoporosis after menopause. The patch gives doctors another way to prescribe estrogen, as a skin patch instead of a pill.

The label says to use the lowest dose that works, for the shortest time that meets your treatment goals, and to check in with your doctor regularly. If you are using it only for vaginal dryness, vaginal products applied directly should be tried first. If you are using it only to prevent osteoporosis, non-estrogen medicines should be tried first. Estrogen is reserved for women at real risk of osteoporosis.

For women who still have a uterus, the label suggests considering a progestogen to lower the risk of cancer of the uterus lining. Estrogen therapy has known risks, so this approval does not mean it is right for everyone.

Talk with your doctor about your own symptoms, health history, and choices. Only you and your doctor can decide whether this treatment fits your needs.

What this means for you:

A new estradiol patch is approved for menopause symptoms and bone loss, but it is not right for everyone.

Study Details

Study typeFda approval

PublishedJul 1996

View Original Abstract ↓

1 INDICATIONS AND USAGE Vivelle-Dot is indicated for: Vivelle-Dot is an estrogen indicated for: • Treatment of moderate to severe vasomotor symptoms due to menopause ( 1.1 ) • Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause ( 1.2 ) Limitations of Use When prescribing solely for the treatment of moderate to severe vaginal atrophy, first consider the use of topical vaginal products. • Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure ( 1.3 ) • Prevention of postmenopausal osteoporosis ( 1.4 ) Limitations of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause . 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Due to Menopause Limitations of Use : When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, first consider the use of topical vaginal products. 1.3 Treatment of Hypoestrogenism Due to Hypogonadism, Castration, or Primary Ovarian Failure . 1.4 Prevention of Postmenopausal Osteoporosis Limitations of Use : When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.

FDA approved Vivelle-Dot (Estradiol Transdermal) for Menopausal Symptoms and Osteoporosis PreventionFDA approved Estradiol Skin Patch for Menopause Symptoms and Bone Loss

Study Details

Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC

New data shows specific drug combinations improve triple-negative breast cancer outcomes

Clinical research that matters. Delivered to your inbox.

FDA approved Vivelle-Dot (Estradiol Transdermal) for Menopausal Symptoms and Osteoporosis PreventionFDA approved Estradiol Skin Patch for Menopause Symptoms and Bone Loss

Study Details

Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC

New data shows specific drug combinations improve triple-negative breast cancer outcomes

Clinical research that matters. Delivered to your inbox.

Related in OB/GYN & Women's Health

From Other Specialties